Replies to post #16490 on Celsion Corporation (CLSN)

[Biobonic]

[GD]

Not much time to do DD, we may read the first look
decision PR to continue or stop for efficacy by next
Monday or Tuesday, to continue, 20% down side risk? To
stop for efficay, $12 to $15 price target, IMO. Now
I understand why CLSN chooses HR as target, not P value
the normal trial value designed for interim efficacy,
for best chance to stop for efficacy if OPTIMA is to
repeat the subgroup OS KM curves, IMO. I am betting
stop for efficacy next week, good luck!